PURPOSE: Eight percent of young-adult childhood cancer survivors meet criteria for frailty, an aging phenotype associated with poor health. In the elderly general population, frailty is associated with neurocognitive decline; this association has not been examined in adult survivors of childhood cancer. METHODS: Childhood cancer survivors 18-45 years old (≥ 10 years from diagnosis) were clinically evaluated for prefrailty or frailty (respectively defined as ≥ 2 or ≥ 3 of: muscle wasting, muscle weakness, low energy expenditure, slow walking speed, and exhaustion [Fried criteria]) and completed neuropsychologic assessments at enrollment (January 2008-June 2013) and 5 years later. Weighted linear regression using inverse of sampling probability estimates as weights compared differences in neurocognitive decline in prefrail and frail survivors versus nonfrail survivors, adjusting for diagnosis age, sex, race, CNS-directed therapy (cranial radiation, intrathecal chemotherapy, and neurosurgery), and baseline neurocognitive performance. RESULTS: Survivors were on average 30 years old and 22 years from diagnosis; 18% were prefrail and 6% frail at enrollment. Frail survivors declined an average of 0.54 standard deviation (95% CI, -0.93 to -0.15) in short-term verbal recall, whereas nonfrail survivors did not decline (β = .22; difference of βs = -.76; 95% CI, -1.19 to -0.33). Frail survivors declined more than nonfrail survivors on visual-motor processing speed (β = -.40; 95% CI, -0.67 to -0.12), cognitive flexibility (β = -.62; 95% CI, -1.02 to -0.22), and verbal fluency (β = -.23; 95% CI, -0.41 to -0.05). Prefrail and frail survivors experienced greater declines in focused attention (prefrail β = -.35; 95% CI, -0.53 to -0.17; frail β = -.48; 95% CI, -0.83 to -0.12) compared with nonfrail survivors. CONCLUSION: Over approximately 5 years, prefrail and frail young-adult survivors had greater declines in cognitive domains associated with aging and dementia compared with nonfrail survivors. Interventions that have global impact, designed to target the mechanistic underpinnings of frailty, may also mitigate or prevent neurocognitive decline.
PURPOSE: Eight percent of young-adult childhood cancer survivors meet criteria for frailty, an aging phenotype associated with poor health. In the elderly general population, frailty is associated with neurocognitive decline; this association has not been examined in adult survivors of childhood cancer. METHODS: Childhood cancer survivors 18-45 years old (≥ 10 years from diagnosis) were clinically evaluated for prefrailty or frailty (respectively defined as ≥ 2 or ≥ 3 of: muscle wasting, muscle weakness, low energy expenditure, slow walking speed, and exhaustion [Fried criteria]) and completed neuropsychologic assessments at enrollment (January 2008-June 2013) and 5 years later. Weighted linear regression using inverse of sampling probability estimates as weights compared differences in neurocognitive decline in prefrail and frail survivors versus nonfrail survivors, adjusting for diagnosis age, sex, race, CNS-directed therapy (cranial radiation, intrathecal chemotherapy, and neurosurgery), and baseline neurocognitive performance. RESULTS: Survivors were on average 30 years old and 22 years from diagnosis; 18% were prefrail and 6% frail at enrollment. Frail survivors declined an average of 0.54 standard deviation (95% CI, -0.93 to -0.15) in short-term verbal recall, whereas nonfrail survivors did not decline (β = .22; difference of βs = -.76; 95% CI, -1.19 to -0.33). Frail survivors declined more than nonfrail survivors on visual-motor processing speed (β = -.40; 95% CI, -0.67 to -0.12), cognitive flexibility (β = -.62; 95% CI, -1.02 to -0.22), and verbal fluency (β = -.23; 95% CI, -0.41 to -0.05). Prefrail and frail survivors experienced greater declines in focused attention (prefrail β = -.35; 95% CI, -0.53 to -0.17; frail β = -.48; 95% CI, -0.83 to -0.12) compared with nonfrail survivors. CONCLUSION: Over approximately 5 years, prefrail and frail young-adult survivors had greater declines in cognitive domains associated with aging and dementia compared with nonfrail survivors. Interventions that have global impact, designed to target the mechanistic underpinnings of frailty, may also mitigate or prevent neurocognitive decline.
Authors: Melissa M Hudson; Matthew J Ehrhardt; Nickhill Bhakta; Malek Baassiri; Hesham Eissa; Wassim Chemaitilly; Daniel M Green; Daniel A Mulrooney; Gregory T Armstrong; Tara M Brinkman; James L Klosky; Kevin R Krull; Noah D Sabin; Carmen L Wilson; I-Chan Huang; Johnnie K Bass; Karen Hale; Sue Kaste; Raja B Khan; Deo Kumar Srivastava; Yutaka Yasui; Vijaya M Joshi; Saumini Srinivasan; Dennis Stokes; Mary Ellen Hoehn; Matthew Wilson; Kirsten K Ness; Leslie L Robison Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-12-29 Impact factor: 4.254
Authors: Katherine A Gifford; Susan P Bell; Dandan Liu; Jacquelyn E Neal; Maxim Turchan; Avantika S Shah; Angela L Jefferson Journal: J Am Geriatr Soc Date: 2019-05-16 Impact factor: 5.562
Authors: Brenda J Spiegler; Eric Bouffet; Mark L Greenberg; James T Rutka; Donald J Mabbott Journal: J Clin Oncol Date: 2004-02-15 Impact factor: 44.544
Authors: Wei Liu; Yin Ting Cheung; Heather M Conklin; Lisa M Jacola; DeoKumar Srivastava; Vikki G Nolan; Hongmei Zhang; James G Gurney; I-Chan Huang; Leslie L Robison; Ching-Hon Pui; Melissa M Hudson; Kevin R Krull Journal: J Cancer Surviv Date: 2018-02-27 Impact factor: 4.442
Authors: Kirsten K Ness; Zhaoming Wang; Nan Song; Zhenghong Li; Na Qin; Carrie R Howell; Carmen L Wilson; John Easton; Heather L Mulder; Michael N Edmonson; Michael C Rusch; Jinghui Zhang; Melissa M Hudson; Yutaka Yasui; Leslie L Robison Journal: Clin Cancer Res Date: 2020-01-22 Impact factor: 12.531
Authors: Jeanne S Mandelblatt; Xingtao Zhou; Brent J Small; Jaeil Ahn; Wanting Zhai; Tim Ahles; Martine Extermann; Deena Graham; Paul B Jacobsen; Heather Jim; Brenna C McDonald; Sunita J Patel; James C Root; Andrew J Saykin; Harvey Jay Cohen; Judith E Carroll Journal: J Natl Cancer Inst Date: 2021-08-02 Impact factor: 13.506
Authors: Jeanne S Mandelblatt; Brent J Small; Gheorghe Luta; Arti Hurria; Heather Jim; Brenna C McDonald; Deena Graham; Xingtao Zhou; Jonathan Clapp; Wanting Zhai; Elizabeth Breen; Judith E Carroll; Neelima Denduluri; Asma Dilawari; Martine Extermann; Claudine Isaacs; Paul B Jacobsen; Lindsay C Kobayashi; Kelly Holohan Nudelman; James Root; Robert A Stern; Danielle Tometich; Raymond Turner; John W VanMeter; Andrew J Saykin; Tim Ahles Journal: J Clin Oncol Date: 2018-10-03 Impact factor: 44.544
Authors: Angela Delaney; Carrie R Howell; Kevin R Krull; Tara M Brinkman; Gregory T Armstrong; Wassim Chemaitilly; Carmen L Wilson; Daniel A Mulrooney; Zhaoming Wang; Jennifer Q Lanctot; Ruth E Johnson; Matthew R Krull; Robyn E Partin; Kyla C Shelton; Deo Kumar Srivastava; Leslie L Robison; Melissa M Hudson; Kirsten K Ness Journal: J Natl Cancer Inst Date: 2021-10-01 Impact factor: 11.816
Authors: Satomi Sato; Nan Li; Stephanie B Dixon; Miho Kato; Hui Zhang; Chi Kong Li; Rebecca M Howell; Wendy M Leisenring; Smita Bhatia; Kevin C Oeffinger; Gregory T Armstrong; Yutaka Yasui; Kevin R Krull; Yin Ting Cheung Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-10-04 Impact factor: 4.254